drugset / Trial / NCT07140055

A Research Study to Evaluate BLX-7006 in Healthy Adults

NCT07140055 ↗

Phase 1 Not yet recruiting 76 enrolled Biolexis Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.

Timeline

Start
2025-09
Primary completion
2026-04
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BLX-7006 Small molecule — Oral

Indications

No indication recorded.